Advertisement

Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B

  • Katarzyna Adamczuk
  • Jolien Schaeverbeke
  • Natalie Nelissen
  • Veerle Neyens
  • Mathieu Vandenbulcke
  • Karolien Goffin
  • Johan Lilja
  • Kelly Hilven
  • Patrick Dupont
  • Koen Van Laere
  • Rik Vandenberghe
Original Article

Abstract

Purpose

Preclinical, or asymptomatic, Alzheimer’s disease (AD) refers to the presence of positive AD biomarkers in the absence of cognitive deficits. This research concept is being applied to define target populations for clinical drug development. In a prospective community-recruited cohort of cognitively intact older adults, we compared two amyloid imaging markers within subjects: 18F-flutemetamol and 11C-Pittsburgh compound B (PIB).

Methods

In 32 community-recruited cognitively intact older adults aged between 65 and 80 years, we determined the concordance between binary classification based on 18F-flutemetamol versus 11C-PIB according to semiquantitative assessment (standardized uptake value ratio in composite cortical volume, SUVRcomp) and, alternatively, according to visual reads. We also determined the correlation between 18F-flutemetamol and 11C-PIB SUVR and evaluated how this was affected by the reference region chosen (cerebellar grey matter versus pons) and the use of partial volume correction (PVC) in this population.

Results

Binary classification based on semiquantitative assessment was concordant between 18F-flutemetamol and 11C-PIB in 94 % of cases. Concordance of blinded binary visual reads between tracers was 84 %. The Spearman correlation between 18F-flutemetamol and 11C-PIB SUVRcomp with cerebellar grey matter as reference region was 0.84, with a slope of 0.98. Correlations in neocortical regions were significantly lower with the pons as reference region. PVC improved the correlation in striatum and medial temporal cortex.

Conclusion

For the definition of preclinical AD based on 18F-flutemetamol, concordance with 11C-PIB was highest using semiquantitative assessment with cerebellar grey matter as reference region.

Keywords

Amyloid PET Biomarker Alzheimer’s disease Preclinical AD 

Notes

Acknowledgements

We would like to thank the staff of Nuclear Medicine, Neurology, and Radiology at the University Hospitals Leuven. Special thanks to Carine Schildermans, Dorien Timmers, Kwinten Porters and Mieke Steukers for help with the study.

Compliance with ethical standards

Funding

This study was funded by the Foundation for Alzheimer Research SAO-FRMA (grant numbers 09013, 11020, 13007); Research Foundation Flanders (grant number G.0660.09); KU Leuven (grant numbers OT/08/056, OT/12/097); IWT VIND; IWT TGO BioAdapt AD; Belspo IAP (grant number P7/11); Research Foundation Flanders senior clinical investigator grant to R.V. and K.V.L.; Research Foundation Flanders doctoral fellowship to K.A; and KH is supported by the Research Fund KU Leuven (grant numbers OT/11/087 and CREA/14/023). 18F-Flutemetamol was provided by GE Healthcare free of charge for this academic investigator-driven trial.

Conflicts of interest

Katarzyna Adamczuk, Jolien Schaeverbeke, Natalie Nelissen, Veerle Neyens, Mathieu Vandenbulcke, Karolien Goffin, Johan Lilja, Kelly Hilven, Patrick Dupont and Koen Van Laere declare that they have no conflicts of interest. Rik Vandenberghe was the PI of the phase 1 and 2 18F-flutemetamol trials. UZ Leuven has had a clinical trial agreement for these trials with GE Healthcare. RV has a consultancy agreement with GE Healthcare. 18F-Flutemetamol was provided by GE Healthcare for the conduct of reported investigator-driven trial free of cost.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:280–92.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9:1118–27.CrossRefPubMedGoogle Scholar
  3. 3.
    Knopman DS, Jack JC, Wiste HJ, Weigand SD, Vemuri P, Lowe V, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576–82.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12:957–65.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, Brooks DJ, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009;50:818–22.CrossRefPubMedGoogle Scholar
  6. 6.
    Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F18). J Nucl Med 2010;51:913–20.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19.CrossRefPubMedGoogle Scholar
  10. 10.
    Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319–29.Google Scholar
  11. 11.
    Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2014;41:290–300.CrossRefPubMedGoogle Scholar
  12. 12.
    Jagust WJ. Amyloid imaging: coming to a PET scanner near you. Ann Neurol 2010;68:277–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Cselényi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med 2012;53:415–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Vandenberghe R, Adamczuk K, Dupont P, Van Laere K, Chételat G. Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer’s disease. Neuroimage Clin 2013;2:497–511.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia. J Nucl Med 2013;54:880–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Adamczuk K, De Weer AS, Nelissen N, Chen K, Sleegers K, Bettens K, et al. Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ε4 carriers. Neuroimage Clin 2013;2:512–20.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Adamczuk K, De Weer AS, Nelissen N, Dupont P, Sunaert S, Bettens K, et al. Functional changes in the language network in response to increased amyloid deposition in cognitively intact older adults. Cereb Cortex. 2014. doi: 10.1093/cercor/bhu286.
  18. 18.
    Nelissen N, Vandenbulcke M, Fannes K, Verbruggen A, Peeters R, Dupont P, et al. Abeta amyloid deposition in the language system and how the brain responds. Brain 2007;130:2055–69.CrossRefPubMedGoogle Scholar
  19. 19.
    Ahmad R, Goffin K, Van den Stock J, De Winter FL, Cleeren E, Bormans G, et al. In vivo type 1 cannabinoid receptor availability in Alzheimer’s disease. Eur Neuropsychopharmacol 2014;24:242–50.CrossRefPubMedGoogle Scholar
  20. 20.
    Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med 2014;55:1623–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Müller-Gärtner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2013;12:357–67.CrossRefPubMedGoogle Scholar
  24. 24.
    Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Sr MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015;11:1–15.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Katarzyna Adamczuk
    • 1
    • 2
  • Jolien Schaeverbeke
    • 1
    • 2
  • Natalie Nelissen
    • 1
    • 3
  • Veerle Neyens
    • 1
    • 2
  • Mathieu Vandenbulcke
    • 4
  • Karolien Goffin
    • 5
  • Johan Lilja
    • 6
    • 7
  • Kelly Hilven
    • 8
  • Patrick Dupont
    • 1
    • 2
  • Koen Van Laere
    • 2
    • 5
  • Rik Vandenberghe
    • 1
    • 2
    • 9
  1. 1.Laboratory for Cognitive NeurologyKU LeuvenLeuvenBelgium
  2. 2.Alzheimer Research Centre KU LeuvenLeuven Institute of Neuroscience and DiseaseLeuvenBelgium
  3. 3.Department of PsychiatryOxford UniversityOxfordUK
  4. 4.Old Age Psychiatry DepartmentUniversity Hospitals LeuvenLeuvenBelgium
  5. 5.Nuclear Medicine and Molecular Imaging DepartmentKU Leuven and University Hospitals LeuvenLeuvenBelgium
  6. 6.GE HealthcareUppsalaSweden
  7. 7.Uppsala UniversityDepartment of Surgical Sciences, Radiology, Uppsala University HospitalUppsalaSweden
  8. 8.Laboratory for NeuroimmunologyKU LeuvenLeuvenBelgium
  9. 9.Neurology DepartmentUniversity Hospitals LeuvenLeuvenBelgium

Personalised recommendations